title: [Amyloid polyneuropathies--biochemical and genetic aspects].
abstract: Familial amyloid polyneuropathies (FAP) are among the most frequent hereditary amyloidoses. These are serious, most often fatal diseases with autosomal dominant inheritance. FAP can be caused by mutations in four genes, namely those encoding transthyretin, Al-apoliprotein, gelsolin, and beta-2 microglobulin. Transthyretin is a tetramer composed of four identical subunits linked by non covalent bonds and bearing binding sites for thyroxine (T4) and retinol-binding protein (RBP). More than 120 transthyretin gene sequence variations have been characterized, of which only 80% seem to be pathogenic. Gene mutations can induce tetramer destabilization, thereby generating misfolded monomers that aggregate into insoluble amyloidfibrils. The mutation spectrum is highly variable across countries. For example, while the Val30Met mutation is found in 95% of the Portuguese and Swedish patient populations, high mutational heterogeneity is observed in France. Age of onset and clinical signs are influenced by numerous factors, especially the mutation type and the country, but the mechanisms underlying this variability are not fully clear. The three-dimensional structure of the normal transthyretin protein and a dozen mutants is now known, providing insights into the deleterious effects of mutations. A better understanding of the mechanisms involved in amyloid fibril formation has led to the development of drugs that inhibit transthyretin tetramer destabilization. It is hoped that, within afew years, such drugs will replace liver transplantation, which is currently the only curative treatment.
authors.affiliation: Biochimie et génétique moléculaire, Centre hospitalier Cochin, 75679 Paris cedex 14. marc.delpech@inserm.fr
authors.forename: Marc
authors.initials: M
authors.lastname: Delpech
authors.forename: Sophie
authors.initials: S
authors.lastname: Valleix
mesh_terms: D000682:Amyloid / Q000187:drug effects; D028227:Amyloid Neuropathies, Familial / Q000235:genetics* / Q000601:surgery; D000818:Animals; D016632:Apolipoprotein A-I / Q000235:genetics; D004195:Disease Models, Animal; D005340:Fibrinogen / Q000378:metabolism; D018260:Gelsolin / Q000235:genetics; D005799:Genes, Dominant; D018740:Genetic Heterogeneity; D006801:Humans; D016031:Liver Transplantation; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D011228:Prealbumin / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D011487:Protein Conformation; D054839:Retinol-Binding Proteins, Plasma / Q000378:metabolism; D013329:Structure-Activity Relationship; D001613:beta 2-Microglobulin / Q000235:genetics
chemical_list: D000682:Amyloid; D016632:Apolipoprotein A-I; D018260:Gelsolin; D011228:Prealbumin; D054839:Retinol-Binding Proteins, Plasma; D001613:beta 2-Microglobulin; D005340:Fibrinogen